BioClinica's Jonathan Andrus Named Chair of DIA's eClinical SIAC.

- Company's Experts Contribute to Industry Collaboration and Standards -

SAN DIEGO -- Bio-Imaging Technologies, Inc., (NASDAQ: BITI) d/b/a BioClinica a leading global provider of clinical trial services, announced today that Jonathan Andrus, Vice President, Clinical Data Management & Regulatory Operations at BioClinica's eClinical Service Division, has been elected as the Drug Information Association (DIA) North American Special Interest Area Communities (SIAC) eClinical Chair.

Jonathan Andrus' term as Chair will begin on July 1, 2009. As a group, the SIACs provide a forum for volunteers to network and exchange information within the pharmaceutical industry. SIACs also assist DIA in identifying professional development needs in particular interest areas and provide information to members in career and professional development. They also promote education, training, and development of professionals in the biopharmaceutical and healthcare industries which include staff of sponsors, vendor organizations, contract research organizations, and sites that implement, apply, and maintain electronic and other new information technologies, processes, and standards in the conduct of clinical trials.

"We're thrilled for Jonathan for his achievement, a testament to the passion and dedication shown towards the industry and his work," said Mark Weinstein, President and CEO of BioClinica. "It's employees like him that make BioClinica an industry leader. With a legacy of more than two successful decades, BioClinica has an established history of service and reliability to the industry. We are looking forward to continuing our leadership for decades to come."

Jonathan Andrus manages regulatory compliance, data management, and training for BioClinica's eClinical Service Division. Prior to joining BioClinica, he managed clinical system validations and Part 11 & HIPAA assessments, and conducted computer system audits with Taratec Development Corporation. He has a Masters of Science in Quality Assurance and Regulatory Affairs from Temple University's Graduate School of Pharmacy, a Bachelor of Arts from Temple University's College of Arts and Sciences, and is a certified quality auditor (CQA) and certified clinical data manager (CCDM). His professional affiliations include the Drug Information Association, the Society for Clinical Data Management, the American Society for Quality and the Mid-Atlantic Region Society for Quality Assurance. He is also an instructor with the Pharmaceutical Training Institute.

In other company news, Jennifer Price, Senior Director, Clinical Solutions at BioClinica, was awarded the "Best of Show" for her presentation "A Practical Introduction to Clinical Data Acquisition Standards Harmonization (CDASH)" at PharmaSUG 2009. On October 1, 2008, CDASH released the first 16 common CRF streams (or domains) for use by the pharmaceutical industry. The goal when putting together the initial domain streams was to find out which data fields are essential to the analysis of clinical data, and collect only that data in a standard way. The presentation focused on the details and challenges involved in implementing CDASH, and its benefits.

Jennifer Price assists customers with developing and executing strategies to successfully implement eClinical technologies and standards within their organizations. She has 20 years of pharmaceutical industry experience and had focused exclusively on EDC implementations for five years. Jennifer is a Certified Clinical Data Manager (CCDM) and a certified SAS Programmer.

"Jennifer has a great deal of knowledge and enthusiasm for the industry, and it is apparent in everything she does," continued Weinstein. "We are excited that Jennifer was recognized by PharmaSUG and know it is well deserved."

BioClinica's employees have a history of involvement in the industry, helping change and move the industry into the future. At DIA 2009, Chris Conner, Director of product management, is participating in the Clinical Data Interchange Standards Consortium's (CDISC) live healthcare link demonstration at booth 1915. Chris has been instrumental in helping to develop real-world implementation of CDASH and harmonize with HL7. Also, Colin Miller, Senior Vice President, Medical Affairs, is highly involved with numerous organizations, including PhRMA Imaging sub-committee on adjudication and QIBA, and serves as the ICR scientific abstract committee chair.

About BioClinica

Bio-Imaging Technologies, Inc. d/b/a BioClinica is a leading global provider of clinical trials services, helping to support drug and product development efforts through all phases of the clinical trial process. Created from the acquisition of Phoenix Data Systems, Inc. by Bio-Imaging Technologies, Inc., BioClinica offers industry-leading medical image management and best-of-breed electronic data capture to companies in the life sciences industry. In addition, BioClinica offers solutions that combine these core services to maximize efficiency and manageability throughout the entire clinical development process. With more than 2,000 successful trials, BioClinica is unsurpassed in its knowledge and experience, helping bring many of today's drugs from early phase development through final approval. BioClinica operates two state-of-the-art, FDA-compliant core labs in the United States and Europe, with business offices in the United States, France, Germany, United Kingdom and the Netherlands. For more information, please visit www.bioclinica.com.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.